Changfeng Pharmaceutical (02652): ICF004 Completes First Healthy Volunteer Dosing in Phase I Clinical Trial

Zhitong Finance APP News, Changfeng Pharmaceutical (02652) announced that the Phase I clinical trial of ICF004 (Chemical Drug Class 1) (ICF004), an inhaled powder aerosol developed by the Group for the treatment of interstitial lung disease (ILD), has completed the enrollment and dosing of the first healthy subject. The above progress marks that ICF004 has entered the subject dosing stage after being approved to conduct this Phase I clinical trial.